InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,101.36
(
-0.29%
)
US TECH 100
17,267.20
(
-0.25%
)
Dow Jones
38,251.35
(
-0.35%
)
Brent Oil
86.02
(
-1.46%
)
Bitcoin
61,193.00
(
-4.14%
)
Post# of 251649
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: jq1234 post# 209401

Monday, 02/27/2017 10:42:07 AM

Monday, February 27, 2017 10:42:07 AM

Post# of 251649
Look like BMY is hedging in 1st line RCC:


Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma

Companies intend to initiate pivotal trial evaluating CABOMETYX™ (cabozantinib) with Opdivo® (nivolumab) alone or in combination with Yervoy® (ipilimumab) in first-line renal cell carcinoma

Planning additional studies in bladder cancer and hepatocellular carcinoma

http://www.businesswire.com/news/home/20170227005356/en/

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up